ClinicalTrials.gg
CompletedNCT06570655Updated Aug 17, 2026

The Study of Pharmacokinetics and Pharmacodynamics of Huperzine A Injection in Healthy Chinese Subjects

A Phase 1 interventional study of Huperzine A injection and Huperzine A injection in Healthy Subjects, sponsored by Wanbangde Pharmaceutical Group Co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Wanbangde Pharmaceutical Group Co., LTD · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The study used a single-center, open, sequential single-dose design. To evaluate the pharmacokinetics and dose-exposure relationship of huperzine A injection

Read the detailed description

The study was divided into four modes of administration. Administration method of A: intravenous injection (non-blood collection arm), intravenous injection of 0.2mg huperzine A injection. B, C, D Administration methods: 0.1mg, 0.2mg, 0.4mg huperzine A injection was injected intramuscularly into the deltoid muscle of the upper arm (the arm on the non-blood collection side). In each cycle, after fasting for at least 10 hours, the subjects received different dosing regimens according to A sequential single dosing method, that is, each subject received dosing method A first, followed by dosing method B after the cleaning period, dosing method C after the cleaning period, and dosing method D after the cleaning period. The wash-out period between the two doses was 7 days for each subject. To evaluate the pharmacokinetics and dose-exposure relationship of huperzine A injection.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Wanbangde Pharmaceutical Group Co., LTD is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily confirms his or her willingness to participate in a particular trial and signed the written , after having been informed of all aspects of the trial that are relevant to the subject\'s decision to participate.They were fully aware of the adverse reactions and voluntarily signed the written informed consent.
  2. The subjects were able to communicate well with the investigators and complete the trial in accordance with the protocol;
  3. Gender: Chinese male or female;
  4. Age: 18-45 years old (including boundary value);
  5. (BMI) 19.0-26.0 kg/m2 [BMI = weight/height 2 (kg/m2)] (including boundary values), body weight ≥50kg for men and ≥45kg for women.

Exclusion criteria

Exclusion Criteria:

  1. Allergic history to huperzine A or any of its components; Patients with a history of allergy to two or more drugs or foods;
  2. patients who have the following diseases at present, including but not limited to diseases of the respiratory system, circulatory system, digestive system, blood system, endocrine system, immune system, skin system, mental nervous system, ENT and other related diseases;
  3. existing or suspected existing epilepsy, angina pectoris, bronchial asthma, mechanical intestinal obstruction, renal insufficiency, urinary obstruction;
  4. underwent major surgical procedures within 6 months before screening or planned to undergo surgical procedures during the trial;
  5. if the vital signs, physical examination, and laboratory findings are clinically significant;
  6. patients with a history of , , AIDS, syphilis and/or clinically significant abnormalities in one or more of the four hemodialysis tests;
  7. those who had lost blood within 3 months before screening (except physiological blood loss in women) or donated blood ≥200mL or donated blood components (such as plasma, , peripheral blood stem cells, etc.) within 3 months;
  8. use of any drugs that alter liver enzyme activity within 30 days before screening (e.g., inductors-barbiturates, carbamazepine, phenytoin, dexamethasone, etc.; \"Inhibitors - SSRI antidepressants, ciprofloxacin, diltiazem, macrolides, metronidazole, ketoconazole, verapamil.

    Rice, fluoroquinolones);

  9. patients who had used any drugs (including prescription drugs, over-the-counter drugs, Chinese herbal medicine) and health products within 14 days before screening, except topical drugs and eye drops;
  10. vaccinated within 1 month before screening or during the planned trial period and within 1 month after the end of the trial;
  11. participants who participated in a clinical trial and took a drug within 3 months before screening;
  12. had a history of drug abuse within 5 years, and/or used drugs within 3 months before screening, and/or had a history of drug dependence, including herbal medicine, or screened positive for drug abuse;
  13. smokers or those who did not agree to avoid using any tobacco products 48 hours before administration and during hospitalization, or who screened positive for nicotine at the first admission;
  14. Regular drinkers in the preceding 6 months, defined as consuming more than 14 units of alcohol per week (1 unit =360mL of 5% beer or 45mL of 40% spirits or 150mL of 12% wine), Or did not agree to stop alcohol intake 48 hours before administration and during hospitalization, or had a positive breath alcohol test at first admission;
  15. subjects who consumed excessive amounts of tea, coffee and/or caffeinated beverages (> 8 cups, 1 cup =250mL) per day before screening or disagreed with the prohibition of tea, coffee and/or caffeinated beverages 48 hours before drug administration and during hospitalization Or caffeinated foods, grapefruit (grapefruit) and/or grapefruit juice (grapefruit juice), and/or products containing poppy;
  16. have a fertility plan (including sperm and egg donation plans) and/or do not agree to use an effective method (non-drug during the trial) from the time of signing the until 3 months after the last dose of medication.

    Of;

  17. difficulty in venous blood collection (unable to tolerate venipuncture, with a history of dizzy with needles and blood, poor vascular conditions, etc.);
  18. subjects may not be able to complete the study for other reasons or should not be included according to the investigator\'s opinion.

    In addition to the above requirements, female subjects who meet the following conditions should also be excluded:

  19. pregnant or lactating women or those with a positive pregnancy test;
  20. who used oral contraceptives within 30 days before screening;
  21. using long-acting estrogen and/or progestin injections and/or implants within 6 months before screening;
  22. had unprotected sex with a partner within 14 days before screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    experimental group

    The same 12 subjects first received 0.2 mg single dose intravenously, then received intramuscular injection of single-dose 0.1 mg, followed by single-dose 0.2 mg, and finally single-dose 0.4 mg. A wash-out period of 7 days was applied between the doses.

    Drug: Huperzine A injection

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum blood concentration of Huperzine A(Cmax)

    To measure the Cmax of Huperzine A in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  2. PK: Area under the Huperzine A blood concentration-time curve from 0min to the time of last concentration(AUC0-t)

    To measure the AUC0-t of Huperzine A in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  3. PK:Area under the Huperzine A blood concentration-time curve from 0min to the infinity time (AUC0-∞)

    To measure the AUC0-∞ of Huperzine A in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

Secondary outcomes

  1. PD: maximum efficacy(Emax)

    Emax is defined as the maximum activities of red blood cell acetylcholinesterase and calculated as the maximum difference between erythrocyte acetylcholinesterase and baseline value. It is measured in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  2. PD: Area under the efficacy curve(AUEC)

    AUEC is defined as the area under the activity-time curve from 0min to the time of last sample collection, which is adjusted for baseline. It is measured in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  3. PD: Time to reach maximum efficacy(Tmax)

    Tmax(PD) is defined as the time to peak activity of red blood cell acetylcholinesterase. It is measured in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  4. PK: Time to peak maximum concentration of the Huperzine A(Tmax)

    Tmax(PK) is measured in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  5. PK: half life of Huperzine A(t1/2)

    t1/2 is defined as the time to eliminate half blood concentration of Huperzine A and is measured in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  6. PK: λz

    λz is defined as the blood concentration elimination rate constant of terminal phase. It is obtained by semilog linear regression with at least 3 non-zero concentration points of the end elimination phase, and the result is the inverse of the slope. It is measured in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  7. PK: Area under the curve(AUC_%Extrap)

    AUC\_%Extrap is defined as the percentage of residual area which refers to the area under the Huerperzine A blood concentration-time curve. It is measured in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  8. PK: Clearance(CL)

    CL is defined as how many milliliters of Huperzine A in blood are eliminated per unit time, it is calculated by the fomula: CL=D/AUC0-∞ (D refers to the dosage of Huperzine A). It is measured in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  9. PK:Apparent volume of distribution(Vd)

    Vd is defined as the ratio of the amount of drug in the body to the concentration in the blood after the drug has reached homeostasis in the body. It is calculated by the fomula: Vd=CL/λz. It is measured in 4 different periods of sequential administration in 12 healthy subjects.

    Time frame: Day1、Day8、Day15、Day22

  10. PK:Bioavailability(F)

    F is defined as the ratio of the AUC0-∞ of intramuscular administration and AUC0-∞ of intravenous administration

    Time frame: Day1、Day8、Day15、Day22

  11. Urine excretion of Huperzine A.(UE)

    UE is defined as the amout of the Huperzine A excreted in urine during the specific time. It is calculated by the fomula: UE=Cut×Vut(Cut refers to concentration of Huperzine A excreted in urine, Vut refers to the volume of urine).

    Time frame: Baseline、Day15-Day17

  12. Cumulative urinary excretion of Huperzine A(CUE)

    CUE is defined as the total Huperzine A amout excreted in urine during the whole study.

    Time frame: Baseline、Day15-Day17

  13. Urine excretion rate(UER)

    URE is defined as the ratio of the Huperzine A dose excreted in the urine to the dose administered during the specific time period. It is calculated by the fomula: URE=UE/D×100%(D refers to the Huperzine A administration dose)

    Time frame: Baseline、Day15-Day17

  14. Cumulative urinary excretion rate(CUER)

    CURE is defined as the summary of ratio of the Huperzine A dose excreted in the urine to the dose administered during the specific time period. It is calculated by the fomula: CURE=CUE/D×100%(D refers to Huperzine A administration dose).

    Time frame: Baseline、Day15-Day17

  15. Faeces excretion(FE)

    FE is defined as the amout of the Huperzine A excreted in faeces during the whole study. It is calculated by the fomula: FE=Cf×Vf(Cf refers to concentration of Huperzine A in faeces, Vf refers to the volume of faeces).

    Time frame: Baseline、Day15-Day17

  16. Faeces excretion rate(FER)

    FER is defined as the ratio of the Huperzine A doses excreted in the faeces to the dose administered.It is calculated by the fomula: FER=FE/D×100%(D refers to Huperzine A administration dose).

    Time frame: Baseline、Day15-Day17

  17. Metabolites of Huperzine A

    To analyze the metabolites of Huperzine A by the plasma sample during the period of C and D methods administration and urine and faeces sample during the period of C method administration.(The methods of administration is explained in the detailed description)

    Time frame: Day15、Day22

  18. Number of participants with adverse events (AEs) or serious adverse events (SAEs) as assessed by NCI-CTCAE v5.0.

    Time frame: Day1-Day28

07

Study locations

1 site
  • Clinical trial institution of the Zhejiang Xiaoshan hospital
    Hangzhou, China/Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jun 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2024
First posted
Aug 26, 2024
StartActual
May 16, 2024
Primary completionActual
Jun 20, 2024
CompletionActual
Aug 29, 2024
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06570655
Lead sponsor
Wanbangde Pharmaceutical Group Co., LTD
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
May 16, 2024
Primary completion
Jun 20, 2024
Completion
Aug 29, 2024
Last update
Aug 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Huperzine A

Start the discussion